Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase C inhibitor

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 877-886

  Saba, Nakhle S ^a   Levy, Laura S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; AKT; apoptosis; GSK3 ; protein kinase C ; targeted therapeutic

Indexed keywords

3 [1 (3 IMIDAZOL 1 YLPROPYL) 1H INDOL 3 YL] 4 ANILINO 1H PYRROLE 2,5 DIONE; ANTINEOPLASTIC AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; PROTEIN KINASE C BETA INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 79954626212     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.552136     Document Type: Article

References (47)

1. Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008;19:841-858.
2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36:277-285.
3. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165-1176.
4. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997;24:70-82. (Pubitemid 27104905)
5. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-596.
6. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 2003;29:3-10. (Pubitemid 36395518)
7. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
8. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005;105:3434-3441. (Pubitemid 40628183)
9. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs 2008;17:939-944. (Pubitemid 351864330)
10. Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther 2009;8:1772-1778.
11. Jiang XH, Tu SP, Cui JT, et al. Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res 2004;64:5787-5794.
12. Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 2008;106:2436-2448.
13. Spindler KL, Lindebjerg J, Lahn M, Kjaer-Frifeldt S, Jakobsen A. Protein kinase C-beta II (PKC-beta II) expression in patients with colorectal cancer. Int J Colorectal Dis 2009;24:641-645.
14. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008;99:750-759.
15. Vogl UM, Berger W, Micksche M, et al. Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Lett 2009;277:218-226.
16. Holler C, Pinon JD, Denk U, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood 2009;113:2791-2794.
17. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004;101:3118-3123. (Pubitemid 38327744)
18. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res 2007;55:477-486. (Pubitemid 46970734)
19. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-1647.
20. Raab MS, Breitkreutz I, Tonon G, et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009;113:1513-1521.
21. Reyland ME. Protein kinase C and apoptosis. In: Srivastava R, editor. Apoptosis, cell signaling and human disease. Totowa, NJ: Humana Press, Inc; 2007. pp 31-55.
22. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-1789. (Pubitemid 44323246)
23. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8: 68-74. (Pubitemid 34101731)
24. Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 2009;27:23-30.
25. Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004;16: 367-373. (Pubitemid 38595376)
26. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 2008;45:S11-S16.
27. Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19: 590-595. (Pubitemid 47508866)
28. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-253. (Pubitemid 351209293)
29. Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol 2007;20:326-330. (Pubitemid 46348328)
30. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-1746. (Pubitemid 46797955)
31. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374-1383. (Pubitemid 352015802)
32. Shinohara H, Maeda S, Watarai H, Kurosaki T. IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells. J Exp Med 2007;204:3285-3293.
33. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780-786.
34. Deacon EM, Pongracz J, Griffiths G, Lord JM. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 1997;50:124-131. (Pubitemid 27454996)
35. Choi PM, Tchou-Wong KM, Weinstein IB. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol Cell Biol 1990;10: 4650-4657.
36. Tanaka M, Sagawa S, Hoshi J, et al. Synthesis of anilinomonoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett 2004;14:5171-5174. (Pubitemid 39233388)
37. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998;273:33533-33539. (Pubitemid 29005737)
38. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-328. (Pubitemid 34832256)
39. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-6551. (Pubitemid 26413787)
40. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279: 710-714. (Pubitemid 28144551)
41. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789. (Pubitemid 26004411)
42. Serova M, Ghoul A, Benhadji KA, et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol 2006;33:466-478. (Pubitemid 44160726)
43. Li ZY, Liu DP, Liang CC. New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia 2005;19: 183-190.
44. Khwaja A. Akt is more than just a Bad kinase. Nature 1999;401:33-34.
45. Lee KW, Kim SG, Kim HP, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916-1926.
46. Kim SG, Lee SJ. PI3K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci 2007;96:206-213. (Pubitemid 46432017)
47. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-7469. (Pubitemid 41161281)